Expanding CYLD protein in NF-κβ/TNF-α signaling pathway in response to Lactobacillus acidophilus in non-metastatic rectal cancer patients.


Journal

Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512

Informations de publication

Date de publication:
19 Sep 2023
Historique:
received: 21 05 2023
accepted: 12 08 2023
medline: 21 9 2023
pubmed: 19 9 2023
entrez: 19 9 2023
Statut: epublish

Résumé

The CYLD gene is a tumor suppressor, reduced in many cancers. Here, we aimed to investigate CYLD protein level and NF-κβ/TNF-α signaling pathway in rectal cancer patients with Lactobacillus acidophilus (L. acidophilus) consumption. One hundred ten patients with non-metastatic rectal cancer were randomly divided into L. acidophilus probiotic (500 mg, three times daily) and placebo groups for 13 weeks. The expression of CYLD, TNF-α, and NF-κB proteins and the genes involved in the NF-κβ/TNF-α pathway were evaluated using ELISA and qPCR techniques. The survival rate was measured after five years. Unlike the placebo group, the results showed a significant increase in the expression of CYLD protein and tumor suppressor genes, including FOXP3, ROR-γ, Caspase3, GATA3, T-bet, and a considerable decrease in the expression of NF-ҝβ and TNF-α proteins and oncogenes, including STAT3, 4, 5, 6, and SMAD 3, in the probiotic group. A higher overall survival rate was seen after L. acidophilus consumption compared to the placebo group (P < 0.05). L. acidophilus consumption can reduce inflammation factors by affecting CYLD protein and its downstream signaling pathways. A schematic plot of probiotic consumption Effects on the CYLD protein in regulating the NF-ĸβ signaling pathway in colorectal cancer. NF-ĸβ can be activated by canonical and noncanonical pathways, which rely on IκB degradation and p100 processing, respectively. In the canonical NF-κβ pathway, dimmers, such as p65/p50, are maintained in the cytoplasm by interacting with an IκBα protein. The binding of a ligand to a cell-surface receptor activates TRAF2, which triggers an IKK complex, containing -α, -β, -g, which phosphorylates IKK-β. It then phosphorylates IκB-α, leading to K48-ubiquitination and degradation of this protein. The p65/p50 protein freely enters the nucleus to turn on target genes. The non-canonical pathway is primarily involved in p100/RelB activation. It differs from the classical pathway in that only certain receptor signals activate this pathway. It proceeds through an IKK complex that contains two IKK-α subunits but not NEMO. Several materials including peptidoglycan, phorbol, myristate, acetate, and gram-positive bacteria such as probiotics inhibit NF-κB by inducing CYLD. This protein can block the canonical and noncanonical NF-κβ pathways by removing Lys-63 ubiquitinated chains from activated TRAFs, RIP, NEMO, and IKK (α, β, and γ). Moreover, TNF-α induces apoptosis by binding caspase-3 to FADD.

Identifiants

pubmed: 37725175
doi: 10.1007/s12032-023-02170-y
pii: 10.1007/s12032-023-02170-y
doi:

Substances chimiques

Tumor Necrosis Factor-alpha 0
Deubiquitinating Enzyme CYLD EC 3.4.19.12
NF-kappa B 0
CYLD protein, human EC 3.4.19.12

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

302

Subventions

Organisme : Iran University of Medical Sciences
ID : 36001
Organisme : Tehran University of Medical Sciences
ID : 29811

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Sivamaruthi BS, Kesika P, Chaiyasut C. The role of probiotics in colorectal cancer management. Evid-Based Complement Altern Med. 2020. https://doi.org/10.1155/2020/3535982 .
doi: 10.1155/2020/3535982
Molska M, Reguła J. Potential mechanisms of probiotics action in the prevention and treatment of colorectal cancer. Nutrients. 2019;11(10):2453.
doi: 10.3390/nu11102453 pubmed: 31615096 pmcid: 6835638
Daniluk U. Probiotics, the new approach for cancer prevention and/or potentialization of anti-cancer treatment. J Clin Exp Oncol. 2012;1:2.
doi: 10.4172/2324-9110.1000e105
Wollowski I, Rechkemmer G, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr. 2001;73(2):451s-s455.
doi: 10.1093/ajcn/73.2.451s pubmed: 11157356
Lei H, et al. Deubiquitinases in hematological malignancies. Biomarker Research. 2021;9(1):1–23.
doi: 10.1186/s40364-021-00320-w
Terzić J, et al. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101-2114.e5.
doi: 10.1053/j.gastro.2010.01.058 pubmed: 20420949
Jono H, et al. NF-κB is essential for induction of CYLD, the negative regulator of NF-κB: evidence for a novel inducible autoregulatory feedback pathway. J Biol Chem. 2004;279(35):36171–4.
doi: 10.1074/jbc.M406638200 pubmed: 15226292
Pikarsky E, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431(7007):461–6.
doi: 10.1038/nature02924 pubmed: 15329734
Liang H-L, et al. MiR-454 prompts cell proliferation of human colorectal cancer cells by repressing CYLD expression. Asian Pac J Cancer Prev. 2015;16(6):2397–402.
doi: 10.7314/APJCP.2015.16.6.2397 pubmed: 25824771
Sun S. CYLD: a tumor suppressor deubiquitinase regulating NF-κB activation and diverse biological processes. Cell Death Differ. 2010;17(1):25–34.
doi: 10.1038/cdd.2009.43 pubmed: 19373246
Khodaii Z, et al. Novel targets in rectal cancer by considering lncRNA–miRNA–mRNA network in response to Lactobacillus acidophilus consumption: a randomized clinical trial. Sci Rep. 2022;12(1):1–8.
doi: 10.1038/s41598-022-13297-9
Mego M, et al. Probiotic bacteria in cancer patients undergoing chemotherapy and radiation therapy. Complement Ther Med. 2013;21(6):712–23.
doi: 10.1016/j.ctim.2013.08.018 pubmed: 24280481
Rondanelli M, et al. Using probiotics in clinical practice: where are we now? A review of existing meta-analyses. Gut microbes. 2017;8(6):521–43.
doi: 10.1080/19490976.2017.1345414 pubmed: 28640662 pmcid: 5730384
Demers M, Dagnault A, Desjardins J. A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation. Clin Nutr. 2014;33(5):761–7.
doi: 10.1016/j.clnu.2013.10.015 pubmed: 24200199
Flesch AT, et al. Perioperative synbiotics administration decreases postoperative infections in patients with colorectal cancer: a randomized, double-blind clinical trial. Rev Col Bras Cir. 2017;44:567–73.
doi: 10.1590/0100-69912017006004 pubmed: 29267553
Burns MB, et al. Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment. Genome medicine. 2015;7(1):1–2.
doi: 10.1186/s13073-015-0177-8
Zitvogel L, et al. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science. 2018;359(6382):1366–70.
doi: 10.1126/science.aar6918 pubmed: 29567708
Gianotti L, et al. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol: WJG. 2010;16(2):167.
doi: 10.3748/wjg.v16.i2.167 pubmed: 20066735 pmcid: 2806554
Karin M, et al. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2(4):301–10.
doi: 10.1038/nrc780 pubmed: 12001991
Costello CM, et al. Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med. 2005;2(8): e199.
doi: 10.1371/journal.pmed.0020199 pubmed: 16107186 pmcid: 1188246
Rutter M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126(2):451–9.
doi: 10.1053/j.gastro.2003.11.010 pubmed: 14762782
Trompouki E, et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature. 2003;424(6950):793–6.
doi: 10.1038/nature01803 pubmed: 12917689
Bullock M, et al. FOXO
doi: 10.1038/bjc.2013.355 pubmed: 23828518 pmcid: 3721407
Wang W, et al. Overexpressed GATA3 enhances the sensitivity of colorectal cancer cells to oxaliplatin through regulating MiR-29b. Cancer Cell Int. 2020;20(1):1–6.
Dariya B, et al. Targeting STAT proteins via computational analysis in colorectal cancer. Mol Cell Biochem. 2021;476(1):165–74.
doi: 10.1007/s11010-020-03893-6 pubmed: 32840738
Spano J-P, et al. JAK/STAT signalling pathway in colorectal cancer: a new biological target with therapeutic implications. Eur J Cancer. 2006;42(16):2668–70.
doi: 10.1016/j.ejca.2006.07.006 pubmed: 16963263
Koveitypour Z, et al. Signaling pathways involved in colorectal cancer progression. Cell Biosci. 2019;9(1):1–4.
doi: 10.1186/s13578-019-0361-4
Fang T, et al. Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysis. BMC Gastroenterol. 2021;21(1):1–2.
doi: 10.1186/s12876-021-01864-9

Auteurs

Farhad Zamani (F)

Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran.

Solmaz Khalighfard (S)

Research Center on Developing Advanced Technologies, Tehran, Iran.

Mohammad Reza Kalhori (MR)

Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Amirhoushang Poorkhani (A)

Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

Taghi Amiriani (T)

Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

Payam Hosseinzadeh (P)

Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran.

Ebrahim Esmati (E)

Radiotherapy Department, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.

Mahdi Alemrajabi (M)

Surgery Department, School of Medicine, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.

Alireza Nikoofar (A)

Radiotherapy Department, School of Medicine, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.

Fahimeh Safarnezhad Tameshkel (F)

Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran.

Ali Mohammad Alizadeh (AM)

Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran. aalizadeh@sina.tums.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH